Multiple myeloma has long been a killer. Therapies are changing that.
New drugs have made it possible to live much longer with the disease, and some scientists even see a possible cure down the road. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - June 20, 2023 Category: Consumer Health News Authors: Marlene Cimons Source Type: news
ASCO: Cilta-Cel Beneficial for Lenalidomide-Refractory Multiple Myeloma
THURSDAY, June 8, 2023 -- For patients with lenalidomide-refractory multiple myeloma, a single cilta-cel infusion results in lower risk of disease progression or death compared with standard care, according to a study published online June 5 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 8, 2023 Category: Pharmaceuticals Source Type: news
CAR T-Cell Benefit in Lenalidomide-Refractory Myeloma CAR T-Cell Benefit in Lenalidomide-Refractory Myeloma
The CAR T-cell construct was associated with significantly better progression-free survival than standard-of-care multidrug regimens.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Genetically modifying T-cells cuts blood cancer progression by 74%, trial finds
A revolutionary blood cancer treatment that genetically modifies patient cells to fight the disease cuts the risk of it progressing by 74%, a world-first clinical trial has found. The therapy, ciltacabtagene autoleucel, “significantly slows or stops progression” of multiple myeloma in patients who…#carvykti #lenalidomide #oreofeodejide #drbinoddhakal #milwaukee (Source: Reuters: Health)
Source: Reuters: Health - June 5, 2023 Category: Consumer Health News Source Type: news
New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials
(MedPage Today) -- CHICAGO -- More than 70% of patients with heavily pretreated multiple myeloma had responses to the novel bispecific antibody talquetamab plus subcutaneous daratumumab (Darzalex Faspro), a preliminary trial showed.
The higher... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2023 Category: Hematology Source Type: news
CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma
(MedPage Today) -- CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) reduced the risk of disease progression or death compared with standard care in lenalidomide... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2023 Category: Hematology Source Type: news
Genetically modifying T-cells cuts blood cancer progression by 74%, trial finds
Therapy slows multiple myeloma in patients who have stopped responding to other treatments, say researchersA revolutionary blood cancer treatment that genetically modifies patient cells to fight the disease cuts the risk of it progressing by 74%, a world-first clinical trial has found.The therapy, ciltacabtagene autoleucel, “significantly slows or stops progression” of multiple myeloma in patients who have stopped responding to other treatments, according to the study. The results were presented in Chicago at the American Society of Clinical Oncology’s (Asco) annual meeting, the world’s largest cancer conferenc e.C...
Source: Guardian Unlimited Science - June 5, 2023 Category: Science Authors: Andrew Gregory in Chicago Tags: Cancer research Health Medical research Science Society US news Source Type: news
Experimental blood cancer therapy already available in US has 90 PERCENT success rate in new trial
Researchers at Hadassah-University Medical Center in Jerusalem, Israel, have used genetically engineered cells to treat the blood cancer multiple myeloma. It has a 90 percent remission rate. (Source: the Mail online | Health)
Source: the Mail online | Health - May 30, 2023 Category: Consumer Health News Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Susan Molineaux is at it again: Weeks after biotech closes, she lands as CEO of cancer drug startup
The CEO scored big with the multiple myeloma drug Kyprolis, then fizzled with Calithera. Her new company is taking another approach to cancer. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 10, 2023 Category: Health Management Authors: Ron Leuty Source Type: news
Susan Molineaux is at it again: Weeks after biotech closes, she lands as CEO of Para Therapeutics
The CEO scored big with the multiple myeloma drug Kyprolis, then fizzled with Calithera. Her new company is taking another approach to cancer. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 10, 2023 Category: Biotechnology Authors: Ron Leuty Source Type: news
Understanding Hybridoma Technology for Monoclonal Antibody Production
By fusing antibody-producing cells with immortal myeloma cells, researchers produce reliable supplies of highly specific antibodies. (Source: The Scientist)
Source: The Scientist - May 9, 2023 Category: Science Tags: Sponsored Article Source Type: news
Eligibility Criteria May Influence Disparity in Multiple Myeloma Trial Enrollment
MONDAY, May 8, 2023 -- Eligibility criteria may contribute to racial and ethnic disparities in enrollment in multiple myeloma (MM) clinical trials, according to a study published online May 4 in Blood.
Bindu Kanapuru, M.D., from the U.S. Food and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 8, 2023 Category: Pharmaceuticals Source Type: news
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Gu érin-Unresponsive Non-Muscle-Invasive Bladder Cancer
CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administered intravenously) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who are ineligible for, or decline, radical cystectomy. The study demonstrated that 72.7 percent of patients treated wit...
Source: Johnson and Johnson - April 30, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
CAR T Therapy Dramatically Reduces Risk Of Relapse For Multiple Myeloma
A CAR T therapy produced by J&J and Legend Biotech significantly reduces risk of relapse for multiple myeloma patients who have received one to three previous lines of treatment, according to early study results. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 27, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
